Literature DB >> 26748848

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Alice Soragni1, Deanna M Janzen2, Lisa M Johnson1, Anne G Lindgren2, Anh Thai-Quynh Nguyen1, Ekaterina Tiourin2, Angela B Soriaga1, Jing Lu3, Lin Jiang1, Kym F Faull4, Matteo Pellegrini3, Sanaz Memarzadeh5, David S Eisenberg6.   

Abstract

Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26748848      PMCID: PMC4733364          DOI: 10.1016/j.ccell.2015.12.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  57 in total

1.  DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.

Authors:  Stefania Vossio; Emanuele Palescandolo; Natalia Pediconi; Francesca Moretti; Clara Balsano; Massimo Levrero; Antonio Costanzo
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

Review 2.  Inhibition of amyloid formation.

Authors:  Torleif Härd; Christofer Lendel
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

3.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

4.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

5.  Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.

Authors:  Suk-Joon Chang; Melissa Hodeib; Jenny Chang; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2013-06-06       Impact factor: 5.482

6.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

7.  Polyarginine as a multifunctional fusion tag.

Authors:  Stephen M Fuchs; Ronald T Raines
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

8.  p73 in Cancer.

Authors:  Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight
Journal:  Genes Cancer       Date:  2011-04

9.  Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.

Authors:  Kae Hashimoto; Ken-Ichirou Morishige; Kenjiro Sawada; Masahiro Tahara; Rikako Kawagishi; Yoshihide Ikebuchi; Masahiro Sakata; Keiichi Tasaka; Yuji Murata
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

Review 10.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

View more
  102 in total

1.  Cancer: Mutant p53 rescued by aggregation inhibitor.

Authors:  Alexandra Flemming
Journal:  Nat Rev Drug Discov       Date:  2016-02       Impact factor: 84.694

2.  Structure-based inhibitors of amyloid beta core suggest a common interface with tau.

Authors:  Sarah L Griner; Paul Seidler; Jeannette Bowler; Kevin A Murray; Tianxiao Peter Yang; Shruti Sahay; Michael R Sawaya; Duilio Cascio; Jose A Rodriguez; Stephan Philipp; Justyna Sosna; Charles G Glabe; Tamir Gonen; David S Eisenberg
Journal:  Elife       Date:  2019-10-15       Impact factor: 8.140

3.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

Review 4.  TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.

Authors:  Ge Zhou; Zhiyi Liu; Jeffrey N Myers
Journal:  J Cell Biochem       Date:  2016-06-03       Impact factor: 4.429

Review 5.  The activities of amyloids from a structural perspective.

Authors:  Roland Riek; David S Eisenberg
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

6.  A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils.

Authors:  Lorena Saelices; Binh A Nguyen; Kevin Chung; Yifei Wang; Alfredo Ortega; Ji H Lee; Teresa Coelho; Johan Bijzet; Merrill D Benson; David S Eisenberg
Journal:  J Biol Chem       Date:  2019-02-07       Impact factor: 5.157

7.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

8.  Organizing biochemistry in space and time using prion-like self-assembly.

Authors:  Christopher M Jakobson; Daniel F Jarosz
Journal:  Curr Opin Syst Biol       Date:  2017-12-06

9.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

10.  Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.

Authors:  Sebastian Kehrloesser; Christian Osterburg; Marcel Tuppi; Birgit Schäfer; Karen Heather Vousden; Volker Dötsch
Journal:  Cell Death Differ       Date:  2016-07-22       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.